Contact Us
Drug Search Results
More Filters [+]

Amiodarone

Alternative Names: amiodarone, cordarone, nexterone, pacerone
Latest Update: 2024-12-12
Latest Update Note: Clinical Trial Update

Product Description

Amiodarone is used to treat life-threatening heart rhythm problems called ventricular arrhythmias. This medicine is used in patients who have already been treated with other medicines that did not work well. (Sourced from: https://www.mayoclinic.org/drugs-supplements/amiodarone-oral-route/description/drg-20061854)

Mechanisms of Action: CYP3A Inhibitor,CYP2D6 Inhibitor,CYP2C9 Inhibitor,CYP1A2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Tachycardia | Tachycardia, Ventricular | Ventricular Fibrillation | Ventricular Fibrillation

Known Adverse Events: Heart Failure | Tachycardia | Tachycardia, Paroxysmal | Tachycardia, Ventricular | Liver Failure | Cardiac Arrest | Shock, Cardiogenic | Hypotension

Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Amiodarone

Countries in Clinic: United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Atrial Fibrillation

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
AMIOMEND

P2

Recruiting

Atrial Fibrillation

2025-11-01

2018-004202-25

P3

Active, not recruiting

Atrial Fibrillation

2022-05-17

Recent News Events

Date

Type

Title

11/07/2024

News Article

 Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

10/22/2024

News Article

 Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024

10/16/2024

News Article

 XYRA Announces FDA Label Guidance for Managing Atrial Fibrillation with Budiodarone and Wearable Monitoring Devices

08/06/2024

News Article

 Ligand Reports Second Quarter 2024 Financial Results

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions